EBS Emergent Biosolutions Inc

  1. Stocks
  2. Healthcare
  3. NYSE: EBS

Price (delayed)

$4.49

Market cap

$230.22M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.41

Enterprise value

$671.12M

?
Relative Growth: Rel. Growth: 6
Relative Strength: Rel. Strength: 3
Relative Valuation: Rel. Valuation: 37
Relative Profitability: Rel. Profitability: 21

At Emergent, our mission is to protect and enhance life. For over 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared ...

Highlights
Emergent Biosolutions's debt has decreased by 13% YoY
EBS's gross margin is up by 4.5% YoY and by 3.1% QoQ
EBS's quick ratio is up by 42% QoQ but it is down by 2.5% YoY
EBS's gross profit is up by 17% since the previous quarter but it is down by 6% year-on-year
EBS's equity is down by 36% year-on-year and by 35% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.emergentbiosolutions.com
Peers: MRK SIGA CLDX PFE

Key stats

What are the main financial stats of EBS

EBS stock price

How has the Emergent Biosolutions stock price performed over time
Intraday
-1.32%
1 week
-15.44%
1 month
-43.95%
1 year
-48.92%
YTD
-63.67%
QTD
-46.42%

Financial performance

How have Emergent Biosolutions's revenue and profit performed over time
Revenue
$770.2M
Gross profit
$430.3M
Operating income
-$66M
Net income
-$176.8M
Gross margin
55.9%
Net margin
-23%
The company's operating margin has shrunk by 196% QoQ and by 169% YoY
EBS's operating income has plunged by 162% YoY
EBS's gross profit is up by 17% since the previous quarter but it is down by 6% year-on-year
The company's revenue rose by 14% QoQ but it fell by 10% YoY

Price vs fundamentals

How does EBS's price correlate with its fundamentals

Growth

What is Emergent Biosolutions's growth rate over time

Valuation

What is Emergent Biosolutions stock price valuation
EBS P/E details
P/E
N/A
P/B
0.68
P/S
0.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.87
EBS's equity is down by 36% year-on-year and by 35% since the previous quarter
The price to book (P/B) is 32% lower than the last 4 quarters average of 1.0 and 15% lower than the 5-year quarterly average of 0.8
The P/S is 57% below the last 4 quarters average of 0.7 and 50% below the 5-year quarterly average of 0.6
The company's revenue rose by 14% QoQ but it fell by 10% YoY

Efficiency

How efficient is Emergent Biosolutions business performance
EBS's ROS has dropped by 143% year-on-year
EBS's ROIC has shrunk by 142% YoY

Dividends

What is EBS's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did Emergent Biosolutions financials performed over time
The total assets is 44% more than the total liabilities
EBS's quick ratio is up by 42% QoQ but it is down by 2.5% YoY
Emergent Biosolutions's current ratio has increased by 26% from the previous quarter but it has decreased by 4.2% YoY
Emergent Biosolutions's debt is 70% higher than its equity
The debt to equity has soared by 55% QoQ and by 36% YoY
EBS's equity is down by 36% year-on-year and by 35% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.